Physician profile
Theodore James
NPI 1003159559
$3,172.82
in general payments reported to CMS, 2019-2025
12 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,598 · 2020: $118 · 2022: $431 · 2023: $693 · 2024: $176 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848 · Travel and Lodging: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.04 |
| Travel and Lodging | $177.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,007.68 | 2019-2023 | Disposable Distal Attachment, Single Use Electrosurgical Knife Kd-655 |
| Abbvie INC. | $401.20 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $319.27 | 2022-2023 | Gattex, Entyvio |
| Covidien LP | $313.10 | 2019 | |
| Janssen Biotech, INC. | $275.31 | 2019 | |
| Gilead Sciences, INC. | $239.80 | 2023-2024 | Livdelzi, Epclusa |
| Boston Scientific Corporation | $205.90 | 2023-2025 | Axios, X-Tack Endoscopic Helix Tacking System, Acquire |
| Ethicon US, LLC | $117.99 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.07 | 2022 | |
| Lucid Diagnostics INC. | $101.61 | 2023 | |
| Olympus America INC. | $55.36 | 2019 | |
| Axonics, INC. | $19.53 | 2023 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.